Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial

Robert J. Motzer; Paul Russo; Viktor Grünwald; Yoshihiko Tomita; Bogdan Zurawski; Omi Parikh; Sebastiano Buti; Philippe Barthélémy; Jeffrey C. Goh; Dingwei Ye; Alejo Lingua; Jean Baptiste Lattouf; Laurence Albigès; Saby George; Brian Shuch; Jeffrey Sosman; Michael Staehler; Sergio Vázquez Estévez; Burcin Simsek; Julia Spiridigliozzi; Aleksander Chudnovsky; Axel Bex

doi:10.1007/s11523-023-00987-1

Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial

Robert J. Motzer^*, Paul Russo, Viktor Grünwald, Yoshihiko Tomita, Bogdan Zurawski, Omi Parikh, Sebastiano Buti, Philippe Barthélémy, Jeffrey C. Goh, Dingwei Ye, Alejo Lingua, Jean Baptiste Lattouf, Laurence Albigès, Saby George, Brian Shuch, Jeffrey Sosman, Michael Staehler, Sergio Vázquez Estévez, Burcin Simsek, Julia SpiridigliozziAleksander Chudnovsky, Axel Bex

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

This is a summary of a research article reporting Part A of the CheckMate 914 study (NCT03138512; EudraCT 2016-004502-34). Following surgery to remove renal cell carcinoma (RCC), people with a high risk of the cancer returning received nivolumab plus ipilimumab (adjuvant therapy) or placebo to see if this risk was reduced. The results of this study showed that the risk of RCC returning or death was not changed with adjuvant nivolumab plus ipilimumab treatment compared with placebo. In addition, people treated with nivolumab plus ipilimumab had more side effects compared with people treated with placebo (89% versus 57%).

Original language	English (US)
Pages (from-to)	639-641
Number of pages	3
Journal	Targeted Oncology
Volume	18
Issue number	5
DOIs	https://doi.org/10.1007/s11523-023-00987-1
State	Published - Sep 2023

Funding

This study was sponsored by Bristol Myers Squibb and Ono Pharmaceutical. Summary prepared by Christina McManus, PhD, at Envision Pharma Group Limited and funded by Bristol Myers Squibb. Patients treated at Memorial Sloan Kettering Cancer Center were supported in part by Memorial Sloan Kettering Cancer Center Support Grant (Core Grant, number P30 CA008748).

ASJC Scopus subject areas

Oncology
Cancer Research
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11523-023-00987-1

Cite this

Motzer, R. J., Russo, P., Grünwald, V., Tomita, Y., Zurawski, B., Parikh, O., Buti, S., Barthélémy, P., Goh, J. C., Ye, D., Lingua, A., Lattouf, J. B., Albigès, L., George, S., Shuch, B., Sosman, J., Staehler, M., Vázquez Estévez, S., Simsek, B., ... Bex, A. (2023). Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial. Targeted Oncology, 18(5), 639-641. https://doi.org/10.1007/s11523-023-00987-1

@article{cb89b8a0f30f4a30b9b24270ee1a45bd,

title = "Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial",

abstract = "This is a summary of a research article reporting Part A of the CheckMate 914 study (NCT03138512; EudraCT 2016-004502-34). Following surgery to remove renal cell carcinoma (RCC), people with a high risk of the cancer returning received nivolumab plus ipilimumab (adjuvant therapy) or placebo to see if this risk was reduced. The results of this study showed that the risk of RCC returning or death was not changed with adjuvant nivolumab plus ipilimumab treatment compared with placebo. In addition, people treated with nivolumab plus ipilimumab had more side effects compared with people treated with placebo (89% versus 57%).",

author = "Motzer, {Robert J.} and Paul Russo and Viktor Gr{\"u}nwald and Yoshihiko Tomita and Bogdan Zurawski and Omi Parikh and Sebastiano Buti and Philippe Barth{\'e}l{\'e}my and Goh, {Jeffrey C.} and Dingwei Ye and Alejo Lingua and Lattouf, {Jean Baptiste} and Laurence Albig{\`e}s and Saby George and Brian Shuch and Jeffrey Sosman and Michael Staehler and {V{\'a}zquez Est{\'e}vez}, Sergio and Burcin Simsek and Julia Spiridigliozzi and Aleksander Chudnovsky and Axel Bex",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

month = sep,

doi = "10.1007/s11523-023-00987-1",

language = "English (US)",

volume = "18",

pages = "639--641",

journal = "Targeted Oncology",

issn = "1776-2596",

publisher = "Springer Paris",

number = "5",

}

Motzer, RJ, Russo, P, Grünwald, V, Tomita, Y, Zurawski, B, Parikh, O, Buti, S, Barthélémy, P, Goh, JC, Ye, D, Lingua, A, Lattouf, JB, Albigès, L, George, S, Shuch, B, Sosman, J, Staehler, M, Vázquez Estévez, S, Simsek, B, Spiridigliozzi, J, Chudnovsky, A & Bex, A 2023, 'Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial', Targeted Oncology, vol. 18, no. 5, pp. 639-641. https://doi.org/10.1007/s11523-023-00987-1

Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial. / Motzer, Robert J.; Russo, Paul; Grünwald, Viktor et al.
In: Targeted Oncology, Vol. 18, No. 5, 09.2023, p. 639-641.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Summary of Research

T2 - Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial

AU - Motzer, Robert J.

AU - Russo, Paul

AU - Grünwald, Viktor

AU - Tomita, Yoshihiko

AU - Zurawski, Bogdan

AU - Parikh, Omi

AU - Buti, Sebastiano

AU - Barthélémy, Philippe

AU - Goh, Jeffrey C.

AU - Ye, Dingwei

AU - Lingua, Alejo

AU - Lattouf, Jean Baptiste

AU - Albigès, Laurence

AU - George, Saby

AU - Shuch, Brian

AU - Sosman, Jeffrey

AU - Staehler, Michael

AU - Vázquez Estévez, Sergio

AU - Simsek, Burcin

AU - Spiridigliozzi, Julia

AU - Chudnovsky, Aleksander

AU - Bex, Axel

PY - 2023/9

Y1 - 2023/9

N2 - This is a summary of a research article reporting Part A of the CheckMate 914 study (NCT03138512; EudraCT 2016-004502-34). Following surgery to remove renal cell carcinoma (RCC), people with a high risk of the cancer returning received nivolumab plus ipilimumab (adjuvant therapy) or placebo to see if this risk was reduced. The results of this study showed that the risk of RCC returning or death was not changed with adjuvant nivolumab plus ipilimumab treatment compared with placebo. In addition, people treated with nivolumab plus ipilimumab had more side effects compared with people treated with placebo (89% versus 57%).

AB - This is a summary of a research article reporting Part A of the CheckMate 914 study (NCT03138512; EudraCT 2016-004502-34). Following surgery to remove renal cell carcinoma (RCC), people with a high risk of the cancer returning received nivolumab plus ipilimumab (adjuvant therapy) or placebo to see if this risk was reduced. The results of this study showed that the risk of RCC returning or death was not changed with adjuvant nivolumab plus ipilimumab treatment compared with placebo. In addition, people treated with nivolumab plus ipilimumab had more side effects compared with people treated with placebo (89% versus 57%).

UR - http://www.scopus.com/inward/record.url?scp=85169607342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85169607342&partnerID=8YFLogxK

U2 - 10.1007/s11523-023-00987-1

DO - 10.1007/s11523-023-00987-1

M3 - Article

C2 - 37659025

AN - SCOPUS:85169607342

SN - 1776-2596

VL - 18

SP - 639

EP - 641

JO - Targeted Oncology

JF - Targeted Oncology

IS - 5

ER -

Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial

Abstract

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this